<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-IIR-16008212</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-04-03</date_registration>
      <primary_sponsor>Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China. </primary_sponsor>
      <public_title>Effect of autologous hemapoietic stem cell transplantation combined with the infusion of haploidentical granulocyte-colony stimulating factor mobilized peripheral blood mononuclear cells in the treatmen of patients with hematologic malignancies: a multicenter， prospectively randomized controlled study </public_title>
      <acronym />
      <scientific_title>Autologous hemapoietic stem cell transplantation combined with the infusion of haploidentical granulocyte-colony stimulating factor mobilized peripheral blood mononuclear cells improves the outcome of patients with hematologic malignancies</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-04-05</date_enrolment>
      <type_enrolment />
      <target_size>Test Group:38;Control group:38;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=13890</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>II (Phase II study)</phase>
      <hc_freetext>hematologic malignancies</hc_freetext>
      <i_freetext>Test Group:Autologous hemapoietic stem cell transplantation combined with the infusion of haploidentical granulocyte-colony stimulating factor mobilized peripheral blood stem cells;Control group:Autologous hemapoietic stem cell transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Cheng Zhang</firstname>
        <middlename />
        <lastname />
        <address>Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China. </address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13098770350;023-68774209</telephone>
        <email>chzhang2014@163.com</email>
        <affiliation>Department of Hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Cheng Zhang</firstname>
        <middlename />
        <lastname />
        <address>Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China. </address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13098770350;023-68774209</telephone>
        <email>1764180534@qq.com</email>
        <affiliation>Department of Hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. patients with hematologic malignancies with medium-high risk  who achieved over PR after three cycle chemotherapy;
2. Male or Female; Age &lt;60 years; 
3. KPS is over 60 and survival is over three months;
4. No serious systemic organ dysfunction and ECOG performance status of &lt;=2 at study entry;
5. Understand and voluntarily sign an informed consent.</inclusion_criteria>
      <agemin />
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. serious systemic organ dysfunction;
2. Patient with malignant tumor that needs to be treat;
3. The patients with clinical symptom of brain dysfunction or serious psychiosis that can't understand or obey the study;
4. Patients that can't followed up as scheduled;
5. Patients that can't guarantee complete the plan and follow up.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>overall survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>disease-Free survival;Rate of relapse;Time of hematopoietic recovery;Rate of GVHD;Donor chimerism;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>The special foundation for the “1130 project” of Xinqiao Hospital of Third Military Medical University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-07-23</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>